| First Author | Zi Xu YX | Year | 2018 |
| Journal | Cancer Lett | Volume | 415 |
| Pages | 208-216 | PubMed ID | 29222040 |
| Mgi Jnum | J:253816 | Mgi Id | MGI:6110629 |
| Doi | 10.1016/j.canlet.2017.12.001 | Citation | Zi Xu YX, et al. (2018) Prohibitin: A new player in immunometabolism and in linking obesity and inflammation with cancer. Cancer Lett 415:208-216 |
| abstractText | Immunometabolism, which has important implications in cancer biology, has emerged as a major regulator of different immune cell types. Various factors that integrate metabolic switches within immune cells with signal directed program that promote or inhibit their functions remain largely unidentified. Furthermore, sex differences are known to exist in immune functions and cancer incidences in the body and sex steroid hormones are integral component of these differences. However, factors that mediate such differences, and the potential link between the two fundamental aspects of immune cell biology that contributes to sex differences in health and disease remain unexplored. New evidence derived from novel tissue-specific transgenic mouse models of prohibitin (PHB) has revealed its crucial role in sex differences in adipocyte and macrophage functions and a potential role in endocrine-immune crosstalk. This review provides a point of view on the emerging role of PHB in immune functions with special focus on immunometabolism and on the immunomodulatory effects of sex steroids. We propose that PHB plays a crucial role in integrating cell signaling events with metabolic switches, and may serve as a potential target for cancer immunotherapeutic. |
